Sr. Director, Field Medical Affairs

Does it excite you to lead a national field medical organization at the forefront of obesity and metabolic disease, and do you bring seasoned Medical Affairs experience leading leaders? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.

Your new position

As Senior Director, Field Medical Affairs – Obesity, you will lead our national obesity-focused field medical organization through two regional Field Directors (East and West), shaping how we translate scientific strategy into field impact. You'll be a senior voice across US Medical Affairs, Clinical Development, and Commercial, driving KOL engagement and launch readiness for our obesity and metabolic pipeline. This is a role for an experienced leader of leaders ready to build, scale, and elevate a high-performing field team.

We offer exciting responsibilities:

Set the vision, goals, KPIs, and strategic territory plans for the national obesity-focused MSL organization, and lead its scale and evolution

Lead, coach, and performance-manage the East and West Field Directors, holding them accountable for regional execution and team performance

Serve as the senior field medical partner to cross-functional leadership across Medical, Clinical, and Commercial

Shape US thought leader engagement strategy and represent Field Medical leadership in high-level KOL interactions

Build leadership bench strength and scientific excellence across both regions through talent development and succession planning

Lead field medical launch planning and readiness for new obesity assets

Ensure field operations meet regulatory, compliance, and budget standards, with full accountability for resource allocation, and advocate for the needs of the field organization

Your profile

You are a senior Medical Affairs leader who thrives on developing leaders and driving field strategy at scale. You bring credibility with KOLs, comfort operating at a senior cross-functional table, and a track record of leading leaders and building strong MSL organizations through complex launches.

Advanced degree (MD, PhD, PharmD) required

10+ years of Medical Affairs experience, including 5+ years leading MSL teams

Demonstrated experience leading leaders, including managing Field Directors or equivalent people managers

Proven US launch experience, including development of field medical launch plans

Demonstrated success building, scaling, and developing high-performing field organizations

Deep understanding of the US regulatory and compliance landscape governing field medical activities

Willingness to travel up to 40% domestically (field rides, national and regional meetings)

Excellent people-skills, relatable, and fun to work with. Values inquiry, transparency, and open communication.

Your new team

The Senior Director, Field Medical Affairs – Obesity, reports directly to Gabe Smolarz, VP of US Medical Affairs, and leads the field-based Medical Affairs presence for Zealand Pharma's obesity/metabolic health franchise. Two regional Field Directors (East and West) report into this role, each overseeing a portion of the combined MSL team, split geographically by territory. This role sits within a growing US Medical Affairs organization built to support the petrelintide launch, alongside Medical Information, Scientific Communications, and Medical Operations functions. The Senior Director partners closely with US Medical Affairs leadership, Global Medical Affairs, and cross-functional launch teams to ensure consistent scientific engagement and field medical strategy execution nationally.

Let's bond and be bold

We have a unique biotech culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.

Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.

Interested in bonding with us? The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.

About Zealand Pharma

Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas.

We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.

In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease.

Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.